LL LLY Eli Lilly and Company Loading... : Bullish and Bearish Analyst Opinions

US pharma reshoring benefits Lilly and Novartis.

Chip selloff and AI spending concerns drove a broad market decline, with the Nasdaq 100 falling 1.6% and Alphabet dropping 4.4% on reports its AI model is behind schedule, while TSMC's strong results failed to lift sentiment.

AlphaSense reports that AI in healthcare is delivering measurable ROI across pharma, payers, and providers with real-world implementations at UnitedHealth, Eli Lilly, and Sanofi.

Eli Lilly deepens its longstanding presence in neuroscience drugs through a new deal reported by Business.

Eli Lilly announces definitive agreement to acquire AtaiBeckley for its pipeline of neuroplastogen therapies targeting treatment-resistant depression.

Eli Lilly announces acquisition of Ataibeckley for up to $3.8 billion to advance therapies for treatment-resistant depression and other mental health conditions.

Reports Lilly in premium deal negotiations per sourced article; no directional view from speaker beyond sharing the headline.

Author shares European approval news for Wegovy pill/Sema 7.2mg with a bullish reaction, but does not state a buy, position, or actionable forward call for LLY.

Headline reports Novo Nordisk's obesity pill outperforming Eli Lilly's; comparative competitive development, no speaker view.

Tirzepatide's superior profile drives premium growth.

The tweet shares an article analyzing liver safety data for Lilly's Orforglipron, concluding it appears fine for now, but offers no personal position or trade call.

Author endorses MELI as a great list pick, is uncertain on NVO but thinks it's a buy while noting LLY might be the better obvious buy, creating a mixed but overall bullish tone on the sector.

Eli Lilly decade-long vanity biotech play

Eli Lilly decade-long consumer biotech play.

Eli Lilly estimates a second quarter 2026 IPR&D charge of $3.02 per share and acquired IPR&D charges of $2.80 billion pre-tax.

JPMorgan raises its price target on Eli Lilly to $1,400 from $1,300, reflecting increased confidence in the company's growth outlook.

AI accelerates biotech drug discovery

Seeking Alpha reports Medicare's new GLP-1 cost cap and bullish market projections but notes the Quant system rates both stocks a HOLD due to high valuation, making this a research summary rather than a trade call.

US House committee sends letters to Pfizer, Eli Lilly, and Bristol Myers Squibb probing their drug trials in China.

US House Committee sends letters to Pfizer, Eli Lilly, and Bristol Myers Squibb probing their China drug trials.

Eli Lilly's CEO signals the next generation of obesity biotech stocks, and the author lists 5 picks with 10x potential as a thematic read-through basket, not a personal position.

The author views the obesity market as early and sees the real opportunity in next-generation molecules, AI platforms, and access models rather than current leaders.

US Representative Moolenaar sent a letter to Eli Lilly's CEO regarding the company's drug trial in China.

Community consensus from the top comment shows that LLY’s oral weight‑loss pill has generated fewer than 2,000 new scripts per week, two months after launch, while NVO is adding high five‑digit scripts weekly. This massive script gap indicates the market is rejecting LLY’s oral formulation (likely due to efficacy/side‑effect profile vs. NVO’s injectable). If this trend continues, LLY’s near‑term revenue from its obesity pill will miss expectations. Short LLY on the weakness of its pill launch, as the script data points to a failed product rollout that could pressure the stock in the coming quarters. The second commenter notes Mounjaro’s life‑changing effects and believes both companies are eventual winners. LLY’s injectable (Mounjaro) remains strong, and the pill’s low scripts could be temporary due to supply or dosing issues. Price/reimbursement hurdles affect both firms. TICKER: NVO - LONG | confidence: 0.70 | sentiment: +0.70 Speaker: r/stocks community Thesis: The top comment reports NVO is achieving high five‑digit new weekly prescriptions, dramatically outpacing LLY’s oral pill and reinforcing its dominance in the GLP‑1 weight loss market. Strong script momentum signals robust physician and patient adoption, likely translating into accelerating revenue growth. Combined with the second commenter’s view that both companies are “gold mines” once reimbursement expands, NVO is best positioned near‑term. Go long NVO to capture the immediate demand wave evidenced by script data, with a medium‑term catalyst from eventual insurance and social security reimbursement expansion. The thread does not counter NVO’s outlook, but general risks include competition from LLY’s injectable, potential pricing pressure, and regulatory changes. The second commenter sees both companies as eventual winners, implying NVO is not uniquely immune. (Only two trade ideas were extracted because the thread contained only 2 comments with actionable data. No other tickers or directions were explicitly discussed.)

Eli Lilly and Regeneron are among the first companies selected for an FDA initiative to expedite review of new manufacturing facilities, as reported by CNBC.

Eli Lilly and Regeneron are among the first companies selected for an FDA initiative to speed review of new manufacturing facilities, as reported by CNBC.

Own diversified basket across sectors.

The author sarcastically highlights LLY's development of brenipatide for multiple CNS indications, but the tone is mocking rather than a bullish position.

Prefer LLY over UNH on a technical basis — stock is in an established uptrend, suggesting continued momentum in the near term.

Notes LLY price move of 7% as an example of unusual market action; no directional view stated.